Company intelligence / Profile preview

Cyclomedica

Kingsgrove, New South Wales, Australiacyclomedica.com ↗
Ownership
Public · CYC
Development stage
Other
01

Overview

Cyclomedica, through its flagship product Technegas®, is a global leader in nuclear medicine and molecular imaging for respiratory diseases. Technegas® is approved and commercially available in over 65 countries, including recent US FDA approval in 2023. The technology is established as a gold standard for ventilation imaging in the diagnosis of pulmonary embolism and is being expanded into broader indications such as COPD, asthma, long COVID, and other chronic lung diseases. Clinical results have demonstrated high diagnostic accuracy and safety across millions of patient procedures worldwide.

Therapeutic areas
OncologyPulmonologyCardiovascular
Modalities
DeviceRadiopharmaceuticalNanoparticle
Industry
Medical Imaging
02

Partnerships

Jubilant Radiopharma/Jubilant Pharma Limited (distribution partnership for RUBY-FILL® cardiac PET agent in EEA)
03

Financials

Market cap
$161.3M
Total revenue
$0
Enterprise value
$111.3M

Beyond the preview

Go deeper on Cyclomedica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclomedica.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call